抗凝血药物研究进展  

Research Progress of Anticoagulant Drugs

作　　者：赵明明 陈国良[2] 张树祥[1] Zhao Mingming;Chen Guoliang;Zhang Shuxiang(Beijing Sihuan Pharmaceutical Co.,Ltd.,Beijing 101113;School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]北京四环制药有限公司,北京101113 [2]沈阳药科大学制药工程学院,辽宁沈阳110016

出　　处：《广东化工》2022年第3期117-119,共3页Guangdong Chemical Industry

摘　　要：抗凝剂是血栓栓塞性疾病预防和长期治疗的主要药物。几十年来,华法林一直被用于抗凝治疗。然而,由于华法林的一些缺点,包括需要持续的常规监测、食物和药物相互作用,以及高出血发生率限制了其使用。随着新药的不断研发,目前出现了许多新型更安全的抗凝药物。这些药物起作用迅速,治疗范围相对较广,有的药物不需要凝血监测,使用更加方便。本文对抗凝药物的研究进展进行了综述和展望。Anticoagulants are the main drugs for the prevention and long-term treatment of thromboembolic disease. Warfarin has been used as an anticoagulant for decades. However, its adverse effects, including the need for ongoing routine monitoring, food and drug interactions, and a high incidence of bleeding, limit its application in clinic. With the continuous development of new drugs, there are some new and safer anticoagulant drugs. These drugs work quickly and have a relatively wide range of treatment. Some drugs do not require coagulation monitoring and are more convenient to use. In this paper, the research progress of anticoagulant drugs is reviewed and prospected.

关 键 词：抗凝血药物 血栓 药理性质 临床试验 研究进展 

分 类 号：R973[医药卫生—药品]